CytoDyn Inc. (CYDY)

CytoDyn Cash Flow Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021
Net Income	3.75	-49.84	-79.82	-210.82	-176.47
Depreciation & Amortization	0.02	0.03	0.18	0.78	1.8
Other Amortization	0.41	1.65	2.2	3.05	3.66
Asset Writedown & Restructuring Costs	-	-	-	-	10.05
Stock-Based Compensation	1.61	2.42	4.28	6.24	10.43
Other Operating Activities	1.63	23.11	49.26	127.81	58.08
Change in Inventory	-	-	-	2.06	-79.36
Change in Accounts Payable	-11.33	10.77	-3.1	-2.71	53.01
Change in Other Net Operating Assets	-4.84	0.89	1.9	-4.13	1.23
Operating Cash Flow	-8.77	-10.98	-25.11	-77.72	-117.57
Capital Expenditures	-	-	-	-	-0.12
Investing Cash Flow	-	-	-	-	-0.12
Long-Term Debt Issued	-	2.31	0.9	-	100
Total Debt Issued	-	2.31	0.9	-	100
Long-Term Debt Repaid	-0.71	-	-	-	-0.95
Total Debt Repaid	-0.71	-	-	-	-0.95
Net Debt Issued (Repaid)	-0.71	2.31	0.9	-	99.05
Issuance of Common Stock	1.19	9.44	26.23	42.62	22.27
Repurchase of Common Stock	-	-	-	-	-0.78
Preferred Dividends Paid	-	-	-	-	-0.24
Dividends Paid	-	-	-	-	-0.24
Other Financing Activities	10.38	-	2.81	5.39	17.05
Financing Cash Flow	10.85	11.75	29.93	48.01	137.35
Net Cash Flow	2.09	0.77	4.82	-29.71	19.65
Free Cash Flow	-8.77	-10.98	-25.11	-77.72	-117.7
Free Cash Flow Margin	-	-	-	-29219.17%	-
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.12	-0.20
Cash Interest Paid	0.03	0.05	0.02	0.06	0.15
Levered Free Cash Flow	-4.3	-43.19	-31.93	-102.87	15.22
Unlevered Free Cash Flow	-1.67	-39.28	-24.44	-90.8	25.38
Change in Working Capital	-16.17	11.66	-1.2	-4.78	-25.12

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.